Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
BD-113 by Shanghai BDgene Therapeutics for Open-Angle Glaucoma: Likelihood of Approval
BD-113 is under clinical development by Shanghai BDgene Therapeutics and currently in Phase II for Open-Angle Glaucoma. According to GlobalData,...